#China #Shanghai #Juncell Therapeutics #TIL therapy

Juncell Therapeutics Launches Advanced Facility for TIL Production

On December 18, 2024, Juncell Therapeutics, a clinical-stage biotech company specializing in innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, officially inaugurated a state-of-the-art manufacturing facility in the Anting International Medical Industry Park located in Jiading District, Shanghai, China. This facility, spanning over 16,000 square meters, is designed to significantly boost the production of TIL products, with an estimated capacity to cater to 6,000 to 10,000 patients each year.

The event marks a pivotal moment in Juncell Therapeutics' journey, following the approval of GC101, the world's first natural TIL therapy free from IL-2 administration, which is currently progressing into a pivotal Phase II clinical trial. The new facility is expected to streamline the development of top-tier TIL products and facilitate the advance of groundbreaking biomedical technologies into effective treatment solutions for patients.

During the opening ceremony, notable attendees included officials from the National Development and Reform Commission, representatives from the Shanghai Municipality, and various clinical experts and investors. Zhou Hanmin, a key figure within the CPPCC National Committee, highlighted the potential of the biopharmaceutical sector, emphasizing the importance of TIL therapy as a cutting-edge advancement in precision medicine.

Lu Zufang, an influential member of the Jiading District Committee, expressed satisfaction at the establishment of the facility, noting it as a testament to successful collaboration between Juncell Therapeutics and governmental bodies. She underscored the company's commitment to addressing unmet needs in solid tumor treatments through innovative approaches.

Attendees also included prominent figures from investment fields who congratulated Juncell on its remarkable achievement and showed keen interest in the company’s future progress. Dr. Jin Huajun, founder of Juncell Therapeutics, conveyed his appreciation to those who supported the inception and growth of the company. He stated that their leading product, GC101, is projected to hit the market by 2026.

Juncell’s commitment to the fight against cancer is exemplified through its advanced production capabilities. The facility’s structure includes a dedicated production center, quality control center, data management center, and operations center, ensuring that all processes meet the highest industry standards. Juncell Therapeutics employs its proprietary DeepTIL® cell expansion and NovaGMP® gene modification platforms, which are designed to overcome the challenges faced by traditional TIL therapies, thus enhancing their accessibility and efficacy for diverse patient groups.

The company has already shown promise with its clinical-stage TIL therapies, evidencing safety and efficacy across various advanced solid tumors, including cancers of the lung, breast, pancreas, and more. Juncell Therapeutics is dedicated to making safe, effective, and affordable TIL therapies widely available, in line with its mission of 'Rebuild cells, Rescue lives'. This revolutionary facility not only represents a milestone for the company but also a leap forward in the realm of cancer treatment, promising hope for countless patients worldwide.

As Juncell Therapeutics embarks on this new chapter, the anticipation surrounding its groundbreaking therapies and the benefits they will bring to patients continues to grow. The company stands ready to lead the charge in transforming cancer care through innovative, high-quality medical solutions.

For more detailed information about Juncell Therapeutics and its endeavors, please visit Juncell's website or their LinkedIn page.